Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00794339 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer
A Phase 2 study, sponsored by American College of Radiology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT00794339 is a Phase 2 study that was terminated before completion, run by American College of Radiology. The registered enrollment target is 73 participants.
The verdict
NCT00794339, a Phase 2 study, was terminated before completion, sponsored by American College of Radiology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures, such as 64Cu-labeled diacetyl-bis\[N4-methylthiosemicarbazone\] (copper Cu 64-ATSM) PET/CT scans, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying how well copper Cu 64-ATSM PET/CT scans work in predicting disease progression in patients undergoing standard of care treatment with cisplatin and radiation therapy (external beam and brachytherapy) per National Comprehensive Cancer Network (NCCN) guidelines for newly-diagnosed stage IB, stage II, stage III, or stage IVA cervical cancer via the Federation of Gynecology and Obstetrics (FIGO) staging systems.
Interventions
- DRUG FDG
- DRUG 64Cu-ATSM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2009-07-29 |
| Est. Completion | 2011-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00794339
The ClinicalTrials.gov registry entry for NCT00794339 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American College of Radiology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FDG is the first listed.
NCT00794339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00794339 about?
NCT00794339 is a clinical study titled "Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer". RATIONALE: Diagnostic procedures, such as 64Cu-labeled diacetyl-bis\[N4-methylthiosemicarbazone\] (copper Cu 64-ATSM) PET/CT scans, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying how well copper Cu 64-ATSM PET/CT scans work in predicting di...
What is the current status of trial NCT00794339?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2009-07-29. Estimated completion is 2011-12-31.
What interventions are being tested in trial NCT00794339?
The interventions under investigation include: FDG (DRUG), 64Cu-ATSM (DRUG).
Who is sponsoring clinical trial NCT00794339?
This trial is sponsored by American College of Radiology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.